PYPD (PolyPid Ltd.) Forward P/E Multiple

Public company logo of PolyPid (PYPD)

High surgeon confidence in PolyPid Ltd. (PYPD) prolonged antibiotic therapy systems stabilizes costs, and the company's expected P/E ratio shown on this GURU.Markets chart confirms this, where 0.00 is the current value of the metric. Business efficiency is based on PLEX robotic packaging, automated synthesis of new drugs, and mandatory medical oversight of clinical trials.

Price to Future Earnings Ratio: PolyPid Ltd. (PYPD) for 07/04/2022 - 11/10/2026

Summary analytical data breakdowns for PolyPid Limited (PYPD)

- current price and projected stock value:
Stock Quotes PolyPid Ltd.|PYPD - Fair Value Consensus
- business market valuation indicators:
Market Capitalization PolyPid Ltd|PYPD - Company Buyout Price
- book capitalization information:
Net Assets per Single Share PolyPid|PYPD - Accounting Capitalization|Market Capitalization to Book Value Ratio polypid.com|PYPD - Total Asset Value of Company
- debt and liquidity details:
Total Debt to Capital PolyPid Ltd.|PYPD - Long-Term Liabilities to Capital|Short-Term Debt to Capital PolyPid Ltd.|PYPD - Company Total Debt|Debt to Book Value PolyPid Ltd|PYPD - Amount of Long-Term Liabilities|Company Short-Term Debts PolyPid|Quick Liquidity polypid.com
- company profitability and valuation multiples indicators:
PYPD - Company Net Income|Expected Profit PolyPid Ltd.|PYPD - Price to Earnings Multiple|Future Price to Earnings PolyPid Ltd.|PYPD - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PolyPid Ltd|PYPD - Profit before deduction of interest, taxes, depreciation and amortization|Earnings per share for the last twelve months PolyPid|PYPD - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months polypid.com|PYPD - Earnings per share growth in current year|Expected earnings per share growth for next year PolyPid Ltd.
Fundamental company analysis:PolyPid PYPD
Brand item of PolyPid Limited

The metric is calculated as the ratio of current market capitalization to expected net income, reflecting the market valuation of future cash flows adjusted for operating expenses. Guaranteed capacity utilization for the production of anti-infective agents stabilizes projected revenues, allowing the 12-month forward P/E of PolyPid Ltd. (PYPD) to assess the asset's fair value and the risks of overpayment.

Key competitors

Projected Price to Earnings SMMT (Summit Therapeutics Inc.)|MRNA (Moderna Inc) - Future Price to Earnings Multiple|Forward P/E Multiple PCVX (Vaxcyte Corp)|Market Cap to Projected Earnings Tarsus Corp (TARS)|CRMD - Future Price to Earnings|MCRB (serestherapeutics.com) - Price to Future Earnings Ratio|SPRO: Forward P/E Multiple|Price to Expected Earnings Ratio SCYX (SCYNEXIS)|ANTX (AN2 Therapeutics Inc) - Forward P/E Multiple|Projected Price to Earnings Ratio YS Biopharma Co., Ltd. LSB|Forward P/E Multiple ITRM|Projected Price to Earnings biomx.com PHGE|Soligenix - Projected Price to Earnings|Market Cap to Future Earnings Ratio SXTP (60 Degrees Pharmaceuticals Inc.)|Oragenics - Forward P/E Multiple|Market Cap to Projected Earnings OpGen Corporation OPGN